CTNM — Contineum Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $452.99m
- $335.08m
- $50.00m
- 28
- 30
- 68
- 37
Annual cashflow statement for Contineum Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -29 | -24.3 | 22.7 |
| Depreciation | |||
| Non-Cash Items | 2.3 | 5.07 | -2.54 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 0.108 | -1.27 | -1.02 |
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Change in Other Liabilities | |||
| Cash from Operating Activities | -26.3 | -20.1 | 19.3 |
| Capital Expenditures | -0.168 | -0.118 | -0.414 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | -64.8 | 22.4 | -65.2 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | -65 | 22.3 | -65.6 |
| Financing Cash Flow Items | 0.096 | -0.004 | -0.371 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 79.8 | -1.24 | 56.2 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -11.4 | 0.939 | 9.96 |